Explain this page
Arphra AIPlain-English read on Crinetics Pharmaceuticals, Inc.’s valuation06-14today
- Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control7d
- Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2026 Earnings Call Transcript44d
- Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Beats Revenue Estimates44d
- Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update45d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$1.96
-94.54% vs spot
Recommendation
Sell
5 of 5 methods
Method spread
0bull5bear
±5% threshold
Analyst PT consensus: $85.14 (+137.36%)
Candlestick · 1Y
Open in chart workstation →CRNX
35.87-27.32%H 50.57L 32.30MA50 36.56MA200 —Avg vol 1.2M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.34% | +3.73% | -3.29% | +0.84% | -25.29% | -22.94% | +19.93% | +82.08% | +76.09% | +46.35% | +46.35% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$246.14K
2 txns
Net flow
−$246.14K
Aftermarket
LiveLast trade
$35.87
368,363 sh
Bid
$35.50
1,000 sh
Ask
$36.24
1,000 sh
Spread
$0.740
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 Dec 2025 | $3.89M | -$122.82M | $-1.30 |
| Q3 Sep 2025 | $143K | -$130.09M | $-1.38 |
| Q2 Jun 2025 | $1.03M | -$115.64M | $-1.23 |
| Q1 Mar 2025 | $361K | -$96.77M | $-1.04 |
| Q4 Dec 2024 | $0 | -$80.6M | $-0.88 |
| Q3 Sep 2024 | $0 | -$76.83M | $-0.96 |
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Controlglobenewswire.com·Jun 14, 2026
- Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2026 Earnings Call Transcriptseekingalpha.com·May 08, 2026
- Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Beats Revenue Estimateszacks.com·May 07, 2026
- Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Updateglobenewswire.com·May 07, 2026
Recent analyst activity
DB- Jun 15, 2026GradeBuy → BuyH.C. Wainwright Reiterates Buy Rating on Crinetics (CRNX)H.C. Wainwright
- Jun 15, 2026PT$81.00H.C. Wainwright Reiterates Buy Rating on Crinetics (CRNX)H.C. Wainwright
- Jun 11, 2026GradeMarket Outperform → Market OutperformCrinetics (CRNX) Reiterated at Market Outperform by CitizensCitigroup
Peers
No peer list available for CRNX.
Total assets
$1.14B
Total debt
$48.54M
Cash & equiv
$101.54M
Operating CF
-$377.92M
Free cash flow
-$383.68M
Buybacks
$0
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Okey Stephanie director | Sell | 608 | $22.02K | Jun 17, 2026 |
Okey Stephanie director | Sell | 6,292 | $224.12K | Jun 17, 2026 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $7.7M | -$516.77M | -$465.32M | $-4.95 | -6046.22% |
| FY 2024 | $1.04M | -$338.85M | -$298.41M | $-3.69 | -28720.69% |
| FY 2023 | $4.01M | -$222.61M | -$214.53M | $-3.69 | -5345.85% |
| FY 2022 | $4.74M | -$167.88M | -$163.92M | $-3.15 | -3460.38% |
| FY 2021 | $1.08M | -$107.7M | -$107.64M | $-2.80 | -9985.25% |